2020 ASCO Virtual Scientific Meeting*

May 29-31, 2020; Online at meetings.asco.org/am
Review slidesets and expert analyses of key data from the 2020 Clinical Oncology Virtual Scientific Meeting!

Gastrointestinal Cancers

Capsule Summary Slidesets

In patients with previously treated HER2+ metastatic CRC, T-DXd associated with a response rate of 45% and durable responses.

Released: June 1, 2020

Neoadjuvant mFOLFIRINOX prior to chemoradiotherapy and total mesorectal excision significantly improved several efficacy outcomes vs preoperative chemoradiotherapy and total mesorectal excision.

Released: June 5, 2020

The addition of neoadjuvant/adjuvant trastuzumab to neoadjuvant chemoradiotherapy and surgery did not improve DFS, OS, or pCR vs trimodality therapy alone in patients with HER2-positive esophageal adenocarcinoma.

Released: June 2, 2020

The S1505 trial failed to meet primary endpoint of 2-year OS rate ≥ 58% with perioperative mFOLFIRINOX or gemcitabine/nab-paclitaxel.

Released: June 4, 2020

In patients with advanced HER2+ gastric/GEJ cancer previously treated with trastuzumab, trastuzumab deruxtecan significantly improved response and OS vs standard chemotherapy.

Released: June 1, 2020

Improvements in both efficacy (PFS, ORR) and safety with single-agent pembrolizumab vs standard therapy.

Released: June 4, 2020
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Daiichi Sankyo, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue